Avenue Therapeutics Inc (ATXI)
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for neurologic diseases. Its pipeline includes AJ201, which is being studied in a Phase 1b/2a clinical trial for spinal and bulbar muscular atrophy, intravenous tramadol for post-operative acute pain, and BAER-101 for epilepsy and panic disorders. Incorporated in 2015 and headquartered in Bay Harbor Islands, Florida, the company operates as a subsidiary of Fortress Biotech, Inc. Avenue Therapeutics’ common stock trades on OTC Markets under the symbol ATXI.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ATXI
|
$0.34
|
30.4% Upside
|
Undervalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.5x
|
0.7x
|
0.6x
|
823.741 K
|
-1.593 M
|
0.0%
|
86.5%
|
-138.5
|
—
|
61.9%
|
